Egerton Capital (UK)’s Gilead Sciences GILD Stock Holding History

Egerton Capital (UK)’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-1,397,732	Closed	-$117M	–	29
2016 Q2	$117M	Sell	1,397,732 -3,123,953	-69%	-$277M	1.31%	24
2016 Q1	$415M	Buy	4,521,685 +230,218	+5%	+$20.8M	3.96%	10
2015 Q4	$434M	Sell	4,291,467 -1,299,329	-23%	-$135M	4.5%	9
2015 Q3	$549M	Buy	5,590,796 +1,591,342	+40%	+$177M	6.2%	3
2015 Q2	$468M	Buy	3,999,454 +3,209,057	+406%	+$351M	5.93%	3
2015 Q1	$77.6M	Sell	790,397 -366,367	-32%	-$37.2M	1.06%	25
2014 Q4	$109M	Sell	1,156,764 -4,542,556	-80%	-$470M	1.46%	24
2014 Q3	$607M	Sell	5,699,320 -449,423	-7%	-$44M	8.16%	2
2014 Q2	$510M	Buy	+6,148,743	New	+$479M	8.07%	2

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Egerton Capital (UK)'s GILD Position: Q3 2016 in Review

Egerton Capital (UK) sold out of Gilead Sciences (GILD) in Q3 2016, closing a stake of 1,397,732 shares — an estimated $117M sold.

Egerton Capital (UK) first reported a position in GILD in Q2 2014 and held it in 9 quarters. The position peaked at $607M in Q3 2014. 1,557 funds tracked by Wall St. Rank hold GILD as of Q3 2016.

Egerton Capital (UK) reported no remaining Gilead Sciences position as of Q3 2016 after selling out during the quarter.
Egerton Capital (UK) sold 1,397,732 Gilead Sciences shares in Q3 2016, an estimated $117M.
Egerton Capital (UK) first reported a position in Gilead Sciences in Q2 2014 and held it in 9 quarters.
Egerton Capital (UK)'s Gilead Sciences position peaked at $607M in Q3 2014.
1,557 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2016.

Based on Egerton Capital (UK)'s 13F filing for Q3 2016, filed 3 Nov 2016.